news
27 Phase III and 8 Phase II Alzheimer’s drugs on track to launch in next 5 years
Twenty-seven Alzheimer's drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years...
List view / Grid view
Alzheimer's
news
Study predicts 1.2 million people in UK will be living with dementia by 2040
By 2040, there will be over 1.2 million people living with dementia in England and Wales (an increase of 57% from 2016), due to increased life expectancy...
news
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease
23 August 2016 | By AstraZeneca
AstraZeneca and Eli Lilly and Company have received US FDA Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in Phase III clinical trial.
news
FDA approves expanded label for Namzaric in Alzheimer’s disease
20 July 2016 | By Victoria White, Digital Content Producer
The US Food and Drug Administration (FDA) has approved an expanded label for Namzaric.
news
Trial of RVT-101 in Alzheimer’s disease starts at Plymouth Science Park
11 July 2016 | By Victoria White, Digital Content Producer
If approved, RVT-101 could be the first Alzheimer’s treatment in 14 years. The last drug to be approved to help improve cognition was Donepezil in 2002...
news
Investigational Alzheimer’s treatment Aducanumab accepted into EMA’s PRIME programme
2 June 2016 | By Victoria White, Digital Content Producer
PRIME aims to bring treatments to patients faster by enhancing the EMA’s support for the development of investigational medicines...
news
Phase II/III trial of AZD3293 in early Alzheimer’s disease to continue
8 April 2016 | By Victoria White
AstraZeneca and Lilly have announced that AMARANTH, a Phase II/III study of AZD3293 will continue into Phase III of the Phase II/III seamless trial...
news
Lilly changes the primary endpoint of the EXPEDITION3 Alzheimer’s trial
15 March 2016 | By Victoria White
Lilly has made a change to the primary endpoint for the EXPEDITION3 clinical trial, a Phase 3 study of solanezumab in people with mild Alzheimer's dementia...
news
Alzheimer’s disease treatment market to more than double by 2021, says GBI Research
11 February 2016 | By Victoria White
GBI Research says the impressive growth in the treatment market will be primarily driven by increased disease prevalence during the forecast period...
article
European Pharmaceutical Review’s top 10 stories from 2015
Mega mergers, 3D printed drugs, a call for action on antimicrobial resistance: 2015 certainly was an interesting year for the pharmaceutical industry. Here we pick a selection of the top stories that hit the headlines.
news
Aridhia’s data platform selected by EPAD for dementia prevention project
19 January 2016 | By Victoria White
The EPAD project is a powerful research collaboration between European organisations in the public and private sectors which focuses on prevention of dementia in the early stages of the disease...
news
MHRA helps make dementia medicine packaging more user-friendly
4 November 2015 | By Victoria White
From June 2016, medicines for the treatment of dementia will include the days of the week clearly on the blister packs...
news
Donepezil may delay residential care for Alzheimer’s sufferers
27 October 2015 | By Victoria White
Withdrawing donepezil from people in the advanced stages of Alzheimer's disease doubles their risk of being placed in a nursing home within a year, according to a UCL study...
news
Resveratrol stabilises Alzheimer’s disease biomarker
14 September 2015 | By Victoria White
Patients who were treated with increasing doses of resveratrol over 12 months showed little or no change in amyloid-beta40 (Abeta40) levels...
news
First patient enrolled in Phase 3 study of aducanumab in Alzheimer’s
8 September 2015 | By Victoria White
Biogen's Phase 3 programme includes two global studies designed to evaluate the efficacy and safety of aducanumab in slowing cognitive impairment and the progression of disability in people with early Alzheimer’s disease...
